ArticleDrug design, development and therapy2026
Association Between Preoperative Single Dose of Dexamethasone and Postoperative Outcomes in Elderly Patients with Gastric Cancer.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimizing postoperative recovery for elderly gastric cancer patients is of great clinical significance. This retrospective cohort study aimed to explore the association between preoperative use of dexamethasone and postoperative outcomes in elderly patients undergoing gastric cancer resection. Methods: In this retrospective cohort study, elderly patients who underwent gastric cancer resection were enrolled. Baseline and perioperative data including use of dexamethasone for antiemetic purpose were collected. Patients were divided into control group (no dexamethasone), low-dose group (< 10 mg) and high-dose group (≥ 10 mg) based on the dose of dexamethasone administered preoperatively on the discretion of anesthesiologists. The primary endpoint was postoperative length of hospital stay (pLOS), defined as the duration from surgery to initial discharge (prolonged pLOS referred to pLOS ≥ median pLOS of all patients). The association between perioperative dexamethasone use and prolonged pLOS were analyzed with multivariable logistic regression models. Dose-response trend test and sensitivity analysis were conducted to confirm the reliability of the findings. Results: The high-dose group had significantly shorter pLOS and lower overall complication rate than the control group (10 [9-13] vs 13 [10-17] days, P = 0.010; 20.9% vs 41.9%, P = 0.011). After adjusting for multiple confounders, preoperative dexamethasone ≥10 mg was independently associated with shorter pLOS (OR 0.355, 95% CI 0.166-0.756, P = 0.007). The high-dose group showed lower risks of pulmonary infection and surgical site infection. Both dexamethasone groups had reduced incidence of acute coronary syndrome. Conclusion: Preoperative dexamethasone ≥10 mg was associated with improved short-term postoperative outcomes in elderly gastric cancer patients, while the dose <10 mg only correlated with lower acute coronary syndrome risk. These observational associations need further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.